MENU
AKTX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Akari Therapeutics (AKTX) Ownership - Who owns Akari Therapeutics?

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads)... Show more

Profile

Industry
Pharmaceuticals Major
Address
22 Boston Wharf Road
Phone
+1 929 274-7510
Employees
12
Web
https://www.akaritx.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
13.92M
P/E Ratio
N/A
Total Cash
2.48M
Projected Growth
N/A
Total Debt
2.12M
Revenue
N/A
Risk (Beta)
-0.45
Dividend Yield
N/A
Total Cash/Share
0.07
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price

Fundamentals

AKTX
Capitalization
13.9M
P/E Ratio
N/A
Risk (Beta)
-0.45
Dividend Yield
N/A
Total Cash
2.48M
Total Cash/Share
0.07
Total Debt
2.12M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
22.7M
P/B Ratio
0.61
Cash Flow
N/A
Earnings
0
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
6.52M
Current Ratio
0.19
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-16.51M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-65.57
Shares Held By Institutions
1.19M
Shares Outstanding - Current
35.7M
Total Liabilities
22.7M
Total Volume MTD
N/A
Value
-1
Gain YTD
-66.393
View a ticker or compare two or three
AKTX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information

General Information

a developer of biopharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
22 Boston Wharf Road
Phone
+1 929 274-7510
Employees
12
Web
https://www.akaritx.com